Radiopharm Theranostics LTD (RADX) — 6-K Filings
All 6-K filings from Radiopharm Theranostics LTD. Browse 4 Foreign Current Report reports with AI-powered summaries and risk analysis.
6-K Filings (4)
-
Radiopharm Theranostics Completes RAD 101 Phase 2b Trial Enrollment
— Apr 16, 2026 Risk: medium
Radiopharm Theranostics Ltd. announced on April 16, 2026, the completion of enrollment for its Phase 2b trial of RAD 101. This marks a significant milestone in - 6-K Filing — Apr 8, 2026
-
Radiopharm Theranostics Signs Supply Deal with Siemens
— Apr 7, 2026 Risk: medium
Radiopharm Theranostics Ltd. announced on April 7, 2026, a clinical supply agreement with Siemens for its RAD101 product. This agreement is a significant step i -
Radiopharm RAD101 Phase 2B Hits 90% Primary Endpoint
— Mar 24, 2026
Radiopharm Theranostics Ltd filed a 6-K on March 24, 2026, announcing positive interim Phase 2B data for its drug RAD101. The filing states that 90% of patients
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX